To test this hypothesis, we performed targeted sequencing for clinical FFPE specimens obtained from rectal cancer patients, and we tried to compare the mutation profiles of the tumor samples pre- and post-treatment, focusing on the TP53 tumor-suppressor gene. The gene discussed is TP53; the disease is rectal cancer.